ArticleDiscover oncology2026
Oncogenic role of C11orf86 in ovarian cancer involving hypoxia response and immune modulation.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundOvarian cancer is often diagnosed at advanced stages and lacks effective biomarkers for prognosis prediction or targeted therapy. The biological role of C11orf86, a previously uncharacterized gene, remains unclear in ovarian cancer.
methodsC11orf86 expression and clinical relevance were analyzed using transcriptomic datasets from TCGA, GTEx, and patient tissues. Functional assays, including siRNA knockdown, overexpression, qPCR, Western blotting, flow cytometry, and Transwell assays, were performed in SKOV3 ovarian cancer cells. Pathway enrichment and immune correlation analyses were conducted using publicly available online databases.
resultsC11orf86 was significantly upregulated in ovarian cancer and associated with poor prognosis, particularly in the TP53-mutant subgroup. Immunohistochemistry confirmed elevated expression of C11orf86 in primary and metastatic ovarian cancer tissues. Functionally, C11orf86 promoted proliferation, migration, invasion, and cell cycle progression of ovarian cancer cells. It was induced by hypoxia and HIF-1α overexpression, while its silencing was accompanied by reduced STAT3 phosphorylation and HIF-1α levels. C11orf86-correlated genes were enriched in cell cycle, hypoxia, and immune-related pathways. Furthermore, C11orf86 expression showed strong correlation with Th2 infiltration and key Th2 markers including STAT5A.
conclusionC11orf86 promotes malignant behaviors in ovarian cancer and may be associated with Th2-related immune features. It is linked to the STAT3-HIF-1α axis and may serve as a promising prognostic biomarker and potential therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.